IRadimed came into this Q3 2026 report with a premium reputation and a premium P/E multiple near 41x, priced as a high quality medical equipment growth story. The stock then dropped about 11% on the first trading day after results. That sharp pullback lands against a quarter that delivered record revenue of US$24.2m and net income of US$6.5m, both supported by a very high gross margin of 76%.

The expectation gap is clear. Trading has punished the shares in the short term while the latest numbers highlight a business still printing strong profitability.

Impressed by IRadimed’s rich margins but uneasy about paying a premium 41x P/E for a growth story that can still get punished on expectations? Compare this earnings print with our 30…